Skip to main content

Home/ Cancer/ Group items tagged PCa CYP17

Rss Feed Group items tagged

Matti Narkia

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependen... - 0 views

  •  
    CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Ang JE, Olmos D, de Bono JS.
    Br J Cancer. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17.
    PMID: 19223900
    doi:10.1038/sj.bjc.6604904
Matti Narkia

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms... - 0 views

  •  
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
    Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.
    J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21.
    PMID: 18645193
    DOI: 10.1200/JCO.2007.15.9749
1 - 2 of 2
Showing 20 items per page